|
||
|
|
|
||
|
|
It is important that physicians remember that whether a patient’s AFib is paroxysmal or permanent, the associated risk for stroke is the same. Many people may believe that because the patient with paroxysmal AFib is going in and out of AFib, that this presents a lower risk of stroke. As seen from the 4 studies shown in the Figure, however, the risk of stroke remains identical, whether the AFib is paroxysmal or permanent.
Rothman SA. Am J Med 2013; 126: 00-00.
[BAATAF= Boston Area Anticoagulation Trial for Atrial Fibrillation; SPAF = Stroke Prevention in Atrial Fibrillation]
[54] Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1515.
[55] Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation study: final results. Circulation. 1991;84:527-539.
[56] Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complication in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-178.
[57] Roy D, Marchand E, Gagne P, Chabot M, Cartier R: Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J. 1986;112:1039-1043.